Lone Hoffmann

PhD Department of Oncology, Aarhus University Hospital lone.hoffmann@aarhus.rm.dk
Research interests

DK:

  • Adaptiv radioterapi til lunge og esophaguscancer
  • Dosis eskalation til lunge og esophaguscancerpatienter
  • Functionel imaging til lungecancerpatienter
  • Intra og interfraktionelle forandringer
  • Gating til lunge og esophaguscancerpatienter
  • Protonterapi til lunge og esophagu cancer
  • Individualiseret RT
  • Optimal dosisplanlægning
  • Dosisplanlægningsalgorithmer

 

 Workgroups Publications
  • Møller DS, Poulsen PR, Hagner A, Dufour M, Nordsmark M, Nyeng TB, Mortensen HR, Lutz CM, Hoffmann L Strategies for Motion Robust Proton Therapy With Pencil Beam Scanning for Esophageal Cancer Int J Radiat Oncol Biol Phys . 2021 Oct 1;111(2):539-548 2021
  • D. Sloth Møller, M.L. Schmidt, T. Ravkilde, P.R. Poulsen, J. Hansen, E.S. Worm, H.H. Schmidt, M.M. Knap, A. Safwat, H.K. Rose, L. Hoffmann Intra-fractional stability of deep inspiration breath hold during rt for lung and lymphoma cancer. Radiotherapy and Oncology Volume 133, Supplement 1, April 2019, Pages S531-S532 2019
  • Hoffmann L, Poulsen PR, Ravkilde T, Bertholet J, Kruhlikava I, Helbo BL, Schmidt ML, Nordsmark M. Setup strategies and uncertainties in esophageal radiotherapy based on detailed intra- and interfractional tumor motion mapping. Radiother Oncol. 2019 Jul;136:161-168. 2019
  • Møller DS, Alber M, Nordsmark M, Nyeng TB, Lutz CM, Hoffmann L Validation of a robust strategy for proton spot scanning for oesophageal cancer in the presence of anatomical changes. Radiother Oncol. pp. 131:174-178 2019
  • Schmidt ML, Hoffmann L, Møller DS, Knap MM, Rasmussen TR, Folkersen BH, Poulsen PR. Systematic intrafraction shifts of mediastinal lymph node targets between setup imaging and radiation treatment delivery in lung cancer patients. Radiother Oncol. 126 (2), pp. 318-324. 2018
  • Shamshad M, Møller DS, Mortensen HR, Ehmsen ML, Jensen MF, Hoffmann L Bone versus soft-tissue setup in proton therapy for patients with oesophageal cancer Acta Oncol . 2022 Jul 1;1-10 2022
  • Hoffmann L, Mortensen H, Shamshad M, Berbee M, Bizzocchi N, Bütof R, Canters R, Defraene G, Ehmsen ML, Fiorini F, Haustermans K, Hulley R, Korevaar EW, Clarke M, Makocki S, Muijs CT, Murray L, Nicholas O, Nordsmark M, Radhakrishna G, Thomas M, Troost EGC, Vilches-Freixas G, Visser S, Weber DC, Møller DS Treatment planning comparison in the PROTECT-trial randomising proton versus photon beam therapy in oesophageal cancer: Results from eight European centres Radiother Oncol . 2022 Jul;172:32-41 2022
  • Hoffmann L, Persson GF, Nygård L, Nielsen TB, Borrisova S, Gaard-Petersen F, Josipovic M, Khalil AA, Kjeldsen R, Knap MM, Kristiansen C, Møller DS, Ottosson W, Sand H, Thing R, Pøhl M, Schytte T Thorough design and pre-trial quality assurance (QA) decrease dosimetric impact of delineation and dose planning variability in the STRICTLUNG and STARLUNG trials for stereotactic body radiotherapy (SBRT) of central and ultra-central lung tumours Radiother Oncol . 2022 Jun;171:53-61 2022
  • Hoffmann L, Knap MM, Khalil AA, Lutz CM, Sloth Møller D. The NARLAL2 dose escalation trial: dosimetric implications of inter-fractional changes in organs at risk Acta Oncol. 2018 Apr;57(4):473-479 2018
  • Jensen MF, Hoffmann L, Petersen JBB, Møller DS, Alber M Energy layer optimization strategies for intensity-modulated proton therapy of lung cancer patients Med Phys. 2018 Oct;45(10):4355-4363 2018
  • Kandi M, Hoffmann L, Sloth Moeller D, Schmidt HH, Knap MM, Khalil AA. Local failure after radical radiotherapy of non-small cell lung cancer in relation to the planning FDG-PET/CT Acta Oncol. 2018 Jun;57(6):813-819 2018
  • Kaplan LP, Elstrøm UV, Møller DS, Hoffmann L. Cone beam CT based dose calculation in the thorax region Phys Imaging Radiat Oncol. 2018 Sep 28;7:45-50 2018
  • Kopp B, Fuglsang Jensen M, Mein S, Hoffmann L, Nyström H, Falk M, Haberer T, Abdollahi A, Debus J, Mairani A FRoG: An independent dose and LETd prediction tool for proton therapy at ProBeam® facilities Med Phys. 2020 Oct;47(10):5274-5286 2020
  • Lutz CM, Knap MM, Hoffmann L, Møller DS, Hansen O, Brink C, Schytte T, Nyhus CH, McCulloch T, Borissova S, Alber M, Khalil AA Prospectively scored pulmonary toxicities in non-small cell lung cancer: Results from a randomized phase II dose escalation trial Clin Transl Radiat Oncol. 2020 Nov 26;27:8-14 2020
  • Zaer H, Glud AN, Schneider BM, Lukacova S, Vang Hansen K, Adler JR, Høyer M, Jensen MB, Hansen R, Hoffmann L, Worm ES, Sørensen JCH, Orlowski D Radionecrosis and cellular changes in small volume stereotactic brain radiosurgery in a porcine model Sci Rep. 2020 Oct 1;10(1):16223 2020
  • Hoffmann L, Knap MM, Alber M, Møller DS Optimal beam angle selection and knowledge-based planning significantly reduces radiotherapy dose to organs at risk for lung cancer patients. Acta Oncol. 2021 Mar;60(3):293-299 2021
  • Holm AIS, Nyeng TB, S Møller D, Assenholt MS, Hansen R, Nyvang L, Ravkilde T, Thomsen MS, Hoffmann L. Density calibrated cone beam CT as a tool for adaptive radiotherapy. Acta Oncol. 2021 Oct;60(10):1275-1282. 2021
  • Khalil AA, Hau E, Gebski V, Grau C, Gee H, Nyeng TB, West K, Kramer S, Farlow D, Knap M, Møller DS, Hoffmann L, Farr KP. Personal innovative approach in radiation therapy of lung cancer- functional lung avoidance SPECT-guided (ASPECT) radiation therapy: a study protocol for phase II randomised double-blind clinical trial BMC Cancer. 2021 Aug 21;21(1):940 2021
  • 'Khalil AA, Knap MM, Møller DS, Nyeng TB, Kjeldsen R, Hoffmann L. Local control after stereotactic body radiotherapy of centrally located lung tumours Acta Oncol. 2021 Aug;60(8):1069-1073 2021
  • Nyeng TB, Møller DS, Farr K, Kramer S, Khalil AA, Grau C, Hoffmann L A comparison of two methods for segmentation of functional volumes in radiotherapy planning of lung cancer patients Acta Oncol. 2021 Mar;60(3):353-360 2021
  • Thomas M, Mortensen HR, Hoffmann L, Møller DS, Troost EGC, Muijs CT, Berbee M, Bütof R, Nicholas O, Radhakrishna G, Defraene G, Nafteux P, Nordsmark M, Haustermans K. Proposal for the delineation of neoadjuvant target volumes in oesophageal cancer. Radiother Oncol. 2021 Mar;156:102-112 2021
  • Møller DS, Lutz CM, Khalil AA, Alber M, Holt MI, Kandi M, Schmidt HH, Tvilum M, Appelt A, Knap MM, Hoffmann L Survival benefits for non-small cell lung cancer patients treated with adaptive radiotherapy Radiother Oncol. 2022 Mar;168:234-240 2022